REFERENCES

• SteinMD.FriedmannPD.Optimizing opioid detoxification: rearranging deck chairs on the Titanic.J Addict Dis.2007261217594992
   PubMed Web of Science ®Google Scholar
• DavisonJW.SweeneyML.BushKR.et al.Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification.J Addict Dis.200625273517088223
   PubMed Web of Science ®Google Scholar
• O'ConnorPG.Methods of detoxification and their role in treating patients with opioid dependence.JAMA.200529496196316118388
   PubMed Web of Science ®Google Scholar
• McCambridgeJ.GossopM.BeswickT.et al.In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.Drug Alcohol Depend,200788919517064857
   PubMed Web of Science ®Google Scholar
• JoeGW.SimpsonDD.BroomeKM.Retention and patient engagement models for different treatment modalities in DATOS.Drug Alcohol Depend.19995711312510617096
   PubMed Web of Science ®Google Scholar
• KleberH.Opioids: detoxification. In: Galanter M, Kleber, HD, eds.Textbook of Substance Abuse Treatment 2nd ed. Washington, DC: American Psychiatric Press;1999251269
   Google Scholar
• MartinWR.JasinskiDR.Physiological parameters of morphine dependence in man: tolerance, early abstinence, protracted abstinence.J Psychiatr Res.196979175352850
   PubMed Web of Science ®Google Scholar
• DartR.Woody.G.KleberH.Prescribing methadone as an analgesic.Ann Intern Med.2005 14362016230741
   PubMed Web of Science ®Google Scholar
• StrangJ.GossopM.Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts.Addict Behav.1990155415472075851
   PubMed Web of Science ®Google Scholar
• GossopM.JohnsA.GreenL.Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment.BMJ (Clin Res Ed).1986293103104
   PubMed Web of Science ®Google Scholar
• BergML.IdreesU.DingR.et al.Evaluation of the use of buprenor-phine for opioid withdrawal in an emergency department.Drug Alcohol Depend20078623924416930865
   PubMed Web of Science ®Google Scholar
• LintzerisN.BellJ.BammerG.et al.A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal.Addiction.20021395140412410780
   PubMed Web of Science ®Google Scholar
• LopatkoOV.WhiteJMHuberA.et al.Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine.Drug Alcohol Depend.200331732212633918
   PubMed Web of Science ®Google Scholar
• BreenCL.HarrisSJ.LintzerisN.et al.Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions.Drug Alcohol Depend200371495512821205
   PubMed Web of Science ®Google Scholar
• CollinsED.KleberHD.WhittingtonRA.et al.Anesthesia-assisted vs. buprenorphine-or clonidine-assisted heroin detoxification and naltrexone induction, A randomized trial.JAMA.200529490391316118380
   PubMed Web of Science ®Google Scholar
• Bochud TornayC.FavratB.MonnatM.et al.Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results.Drug Alcohol Depend.20036928328812633914
   PubMed Web of Science ®Google Scholar
• GowingL.AliR.WhiteJ.Buprenorphine for the management of opioid withdrawal.Cochrane Database Syst Rev.200369283288
   Google Scholar
• GoldMS.RedmondDE.Jr.KleberHD.Clonidine in opiate withdrawal.Lancet.197819293076860
   PubMed Web of Science ®Google Scholar
• CharneyDS.HeningerGR.KleberHD.The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone.Am J Psychiatry.19861438318373717421
   PubMed Web of Science ®Google Scholar
• O'ConnorPG.CarrollKM.ShiJM.et al.Three methods of opioid detoxification in a primary care setting. A randomized trial.Ann Intern Med.19971275265309313020
   PubMed Web of Science ®Google Scholar
• KleberHD.RiordanCE.RounsavilleB.et al.Clonidine in outpatient detoxification from methadone maintenance.Arch Gen Psychiatry.1985423913943977557
   PubMed Web of Science ®Google Scholar
• JasinskiDR.JohnsonRE.KocherR.Clonidine in morphine withdrawal: differential effects on signs and symptoms.Arch Gen Psychiatry.1985106310662413818
   PubMed Web of Science ®Google Scholar
• CarnwathT.Hardman.J.Randomized double-blind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal.Drug Alcohol Depend.19982512549649979
   PubMed Web of Science ®Google Scholar
• KahnA.MumfordJP.Rogers.GA.et al.Double blind study of lofexidine and clonidine in the detoxification of oopiate addicts in hospital.Drug Alcohol Depend.199757619031821
   PubMed Web of Science ®Google Scholar
• BuntwalN.BeamJ.GossopM.et al.Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.Drug Alcohol Depend.20005918318810891632
   PubMed Web of Science ®Google Scholar
• BearnJ.GossopM.StrangJ.Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for inpatient opiate detoxification.Drug Alcohol Depend.1998502272329649976
   PubMed Web of Science ®Google Scholar
• BearnJ.BennettJ.MartinT.et al.The impact of naloxone/Iofexidine combination treatment on the opiate withdrawal syndrome.Addict Biol.2001614715611341854
   PubMed Web of Science ®Google Scholar
• StrangJ.BearnJ.GossopM.Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.Am J Addict.1999833734810598217
   PubMed Web of Science ®Google Scholar
• RiordanCE.KleberHD.Rapid opiate detoxification with clonidine and naloxone.Lancet.19801107910806103408
   PubMed Web of Science ®Google Scholar
• O'ConnorPG.Waugh.M.CarrollK.M. et al.Primary care-based ambulatory opioid detoxification: the results of a clinical trial.J Gen Intern Med.19952552607616334
   PubMed Web of Science ®Google Scholar
• ViningE.KostenTR.KleberHD.Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers.Br J Addict.1988835675753382815
   PubMedGoogle Scholar
• O'ConnorPG.KostenTR.Rapid and ultrarapid opioid detoxification techniques.JAMA.19982792292349438745
   PubMed Web of Science ®Google Scholar
• LoimerN.SchmidRW.PresslichO.et al.Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment.J Psychiatr Res.19892381862547057
   PubMed Web of Science ®Google Scholar
• LoimerN.LenzK.SchmidR.et al.Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.Am J Psychiatry.19911489339352053636
   PubMed Web of Science ®Google Scholar
• LoimerN.HofmannP.ChaudhryH.Ultrashort noninvasive opiate detoxification.Am J Psychiatry.19931508398480840
   PubMed Web of Science ®Google Scholar
• SeoaneA.CarrascoG.CabreL.et al.Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success.Br J Psychiatry.19971713403459373422
   PubMed Web of Science ®Google Scholar
• BrewerC.Ultra-rapid antagonist-precipitated opiate detoxification under general anesthesia or sedation.Addict Biol.19972291302
   PubMed Web of Science ®Google Scholar
• KleberHD.Ultrarapid opiate detoxification.Addiction.199893162916339926526
   PubMed Web of Science ®Google Scholar
• ScherbaumN.KleinS.KaubeH.et al.Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification.Pharmacopsychiatry.19982052099930633
   PubMed Web of Science ®Google Scholar
• CucchiaAT.MonnatM.SpagnoliJ.et al.Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results.Drug Alcohol Depend.1998522432509839150
   PubMed Web of Science ®Google Scholar
• SpanagelR.SillaberI.ZieglgansbergerW.et al.Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress.Psychopharmacology (Berl).19981393914019809860
   PubMed Web of Science ®Google Scholar
• McGregorC.AliR.WhiteJM.et al.A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precurserto maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months.Drug Alcohol Depend.200251412167548
   PubMed Web of Science ®Google Scholar
• DeJongCAJ.LaheijRJF.KrabbePFM.General anesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled tirai.Addiction.200510020621515679750
   PubMed Web of Science ®Google Scholar
• HamiltonRJ.OlmedoRE.ShahS.et al.Complications of ultra-rapid opioid detoxification with subcutaneous naltrexone pellets.Acad Emerg Med.2002636811772672
   PubMed Web of Science ®Google Scholar
• WhittingtonRA.CollinsED.KleberHD.Rapid opioid detoxification during general anesthesia: is death not a significant outcome?Anesthesiology.2000931363136411046233
   PubMed Web of Science ®Google Scholar
• GoldCG.CuIIenDJ.GonzalesS.et al.Rapid opioid detoxification during general anesthesia: a review of 20 patients.Anesthesiology.1999911639164710598605
   PubMed Web of Science ®Google Scholar
• DyerC.Addict died after rapid opiate detoxification.BMJ.19983161709468674
   PubMedGoogle Scholar
• JarvisMA.SchnollSH.Methadone treatment during pregnancy.J Psychoactive Drugs.1994261551617931860
   PubMed Web of Science ®Google Scholar
• CollinsSL.KleberH.Opioids: detoxification. In: Galanter M, Kleber, HD, eds.Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Press;2004265289
   Google Scholar
• JohnsonRE.JonesHE.JasinskiDR.et al.Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes.Drug Alcohol Depend.2001639710311297835
   PubMed Web of Science ®Google Scholar
• SchindlerSD.EderH.OrtnerR.et al.Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy.Addiction.20039810311012492761
   PubMed Web of Science ®Google Scholar
• JonesHE.JohnsonRE.JasinskiDR.et al.Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.Drug Alcohol Depend.20057911015943939
   PubMed Web of Science ®Google Scholar
• FischerG.OrtnerR.RohrmeisterK.et al.Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.Addiction.200610127528116445556
   PubMed Web of Science ®Google Scholar
• LejeuneC.Simmat-DurandL.GourarierL.et al.Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.Drug Alcohol Depend.20068225025716257138
   PubMed Web of Science ®Google Scholar
• DoleVP.NyswanderM.A medical treatment for diacetylmorphine (heroin) addiction, a clinical trial with methadone hydrochloride.JAMA.196519364665014321530
   PubMed Web of Science ®Google Scholar
• DoleVP.NyswanderME.KreekMJ.Narcotic blockade - a medical technique for stopping heroin use by addicts.Trans Assoc Am Physicians.1966791221364162906
   PubMedGoogle Scholar
• DoleVP.NyswanderME.WarnerA.Successful treatment of 750 criminal addicts.JAMA1968206270827115754883
   PubMed Web of Science ®Google Scholar
• BallJC.RossA.The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag;1991
   Google Scholar
• DoleVP.JosephH.Long-term outcome of patients treated with methadone maintenance.Ann N Y Acad Sci.1978311181189283719
   PubMedGoogle Scholar
• HarwoodHJ.HubbardRL.CollinsJJ.et al.The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data.NIDA Res Monogr.1988862092353140032
   PubMedGoogle Scholar
• AmatoL.DavoliM.CAP.et al.An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research.J Subst Abuse Treat.20052832132915925266
   PubMed Web of Science ®Google Scholar
• SchottenfeldRS.Opioids maintenance treatment. In: Galanter M, Kleber HD, eds.Textbook of Substance Abuse Treatment 3rd ed. Washington, DC: American Psychiatric Press;2004291304
   Google Scholar
• McLellanAT.Arndt10.MetzgerDS.et al.The effects of psychosocial services in substance abuse treatment.JAMA.1993269195319598385230
   PubMed Web of Science ®Google Scholar
• GourevitchMN.FriedlandGH.Interactions between methadone and medications used to treat HIV infection: a review.Mt Sinai J Med.20006742943611064494
   PubMed Web of Science ®Google Scholar
• ClarkeSM.MulcahyFM.TjiaJ.et al.The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.Br J Clin Pharmacol.20015121321711298066
   PubMed Web of Science ®Google Scholar
• AlticeFL.FriedlandGH.CooneyEL.Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.AIDS.19991395796210371177
   PubMed Web of Science ®Google Scholar
• McCance-KatzEF.RaineyPM.FriedlandG.et al.The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.Clin Infect Dis.20033747648212905130
   PubMed Web of Science ®Google Scholar
• AkereleEO.LevinF.NunesE.et al.Effects of HIV triple therapy on methadone levels.Am J Addict.20021130831412584873
   PubMed Web of Science ®Google Scholar
• SchottenfeldRS.ChawarskiMC.PakesJR.et al.Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.Am J Psychiatry.200516234034915677600
   PubMed Web of Science ®Google Scholar
• GreensteinRA.FudalaPJ.O'BrienCP.Alternative pharmacotherapies for opiate addiction. In: Lowinson JH, Ruiz P, Millma, RB, Langrod JG, eds.Substance Abuse: a Comprehensive Textbook. Baltimore, Md: Williams and Wilkins;1997
   Google Scholar
• BusterMC.van BrusselGH.van den BrinkW.An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam.Addiction.200297993100112144602
   PubMed Web of Science ®Google Scholar
• DonnyEC.WalshSL.BigelowGE.et al.High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.Psychopharmacology (Berl).200216120221211981600
   PubMed Web of Science ®Google Scholar
• StrainEC.BigelowGE.LiebsonIA.et al.Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.JAMA.19992811000100510086434
   PubMed Web of Science ®Google Scholar
• GrabowskiJ.CresonD.RhoadesHM.et al.Moderate- vs high-dose methadone for opioid dependence.JAMA.19992822121-2; author reply 2122212310591329
   PubMedGoogle Scholar
• GersteinDR.Research: drug abuse. In: Galanter M, Kleber HD, eds.Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Press; 200138140
   Google Scholar
• CaplehornJR.BellJ.Methadone dosage and retention of patients in maintenance treatment.Med J Aust.19911541951991988793
   PubMed Web of Science ®Google Scholar
• KleberHD.GoldMS.Use of psychotropic drugs in treatment of methadone maintained narcotic addicts.Ann N Y Acad Sci.1978311819833588
   PubMedGoogle Scholar
• KreekMJ.Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine.Ann N Y Acad Sci.200090918621610911931
   PubMed Web of Science ®Google Scholar
• KreekMJ.Medical complications in methadone patients.Ann N Y Acad Sci.1978311110134369431
   PubMedGoogle Scholar
• KreekMJ.KoobGF.Drug dependence: stress and dysregulation of brain reward pathways.Drug Alcohol Depend.19985123479716928
   PubMed Web of Science ®Google Scholar
• KrantzMJ.LewkowiezL.HaysH.et al.Torsade de pointes associated with very-high-dose methadone.Ann Intern Med.200213750150412230351
   PubMed Web of Science ®Google Scholar
• FishbainDA.CutlerRB.RosomoffHL.et al.Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidencebased review.J Pain Symptom Manage.20032555957712782437
   PubMed Web of Science ®Google Scholar
• GruberSA.TzilosGK.Silver!MM.et al.Methadone maintenance improves cognitive performance after two months of treatment.Exp Clin Psychopharmacol.20061415716416756419
   PubMed Web of Science ®Google Scholar
• BroonerRK.KidorfMS.KingVL.et al.Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence.Drug Alcohol Depend.200788(suppl2)S14S2317257782
   PubMed Web of Science ®Google Scholar
• SchwartzRP.HighfieldDA.JaffeJH.et al.A randomized controlled trial of interim methadone maintenance.Arch Gen Psychiatry.20066310210916389204
   PubMed Web of Science ®Google Scholar
• SchwartzRP.JaffeJH.HighfieldDA.et al.A randomized controlled trial of interim methadone maintenance: 10-month follow-up.Drug Alcohol Depend.200786303616793221
   PubMed Web of Science ®Google Scholar
• MurrillCS.WeeksH.CastrucciBC.et al.Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.Am J Public Health.20029238538711867316
   PubMed Web of Science ®Google Scholar
• ComptonP.CharuvastraVC.LingW.Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agentDrug Alcohol Depend.2001631394611376918
   PubMed Web of Science ®Google Scholar
• KantorTG.CantorR.TomE.A study of hospitalized surgical patients on methadone maintenance.Drug Alcohol Depend.198061631736107237
   PubMed Web of Science ®Google Scholar
• AlfordDP.ComptonP.SametJH.Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.Ann Intern Med.200614412713416418412
   PubMed Web of Science ®Google Scholar
• MehtaV.LangfordRM.Acute pain management for opioid dependent patients.Anaesthesia.20066126927616480353
   PubMed Web of Science ®Google Scholar
• KlingMA.CarsonRE.BorgL.et al.Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts.J Pharmacol Exp Ther.20002951070107611082442
   PubMed Web of Science ®Google Scholar
• SalsitzEA.JosephH.FrankB.et al.Methadone medical maintenance: treating chronic opioid dependence in private medical practice-a summary report.Mt Sinai J Med.20006738839711064489
   PubMed Web of Science ®Google Scholar
• RosenblumAR.MaguraS.JosephH.Ambivalence towards methadone treatment among intravenous drug users.J Psychoactive Drugs.19912321271941364
   PubMed Web of Science ®Google Scholar
• HarrisKA.Jr.ArnstenJH.JosephH.et al.A 5-year evaluation of a methadone medical maintenance program.J Subst Abuse Treat.20063143343817084798
   PubMed Web of Science ®Google Scholar
• KingVL.KidorfMS.StollerKB.et al.A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model.J Subst Abuse Treat20063138539317084792
   PubMed Web of Science ®Google Scholar
• MerrillJO.JacksonTR.SchulmanBA.et al.Methadone medical maintenance in primary care. An implementation evaluation.J Gen Intern Med.20052034434915857492
   PubMed Web of Science ®Google Scholar
• NovickDM.JosephH.SalsitzEA.et al.Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years.J Gen Intern Med.199491271308195910
   PubMed Web of Science ®Google Scholar
• MetzgerDS.WoodyGE.McLellanAT.et al.Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.J Acquir Immune Defic Syndr.19936104910568340896
   PubMed Web of Science ®Google Scholar
• ZanisDA.WoodyGE.One-year mortality rates following methadone treatment discharge.Drug Alcohol Depend.1998522572609839152
   PubMed Web of Science ®Google Scholar
• CaplehornJR.DaltonMS.HaldarF.et al.Methadone maintenance and addicts' risk of fatal heroin overdose.Subst Use Misuse.1996311771968834006
   PubMed Web of Science ®Google Scholar
• GoldMS.DackisCA.WashtonAM.The sequential use of clonidine and naltrexone in the treatment of opiate addicts.Adv Alcohol Subst Abuse.1984319396388273
   PubMedGoogle Scholar
• SAMHSA.Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. In:Treatment Improvement Protocol (TIP) Series 40. Rockville, Md: DHHS Publication No. (SMA) 04-3939;2004
   Google Scholar
• BIoms-FunkeP.GillenC.SchuettlerAJ.et al.Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.Peptides.2000211141114610998549
   PubMed Web of Science ®Google Scholar
• FudalaPJ.BridgeTP.HerbertS.et al.Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.N Engl J Med.200334994995812954743
   PubMed Web of Science ®Google Scholar
• StrainEC.StitzerML.LiebsonIA.et al.Dose-response effects of methadone in the treatment of opioid dependence.Ann Intern Med.199311923278498759
   PubMed Web of Science ®Google Scholar
• JohnsonRE.JaffeJH.FudalaPJ.A controlled trial of buprenorphine treatment for opioid dependence.JAMA.1992267275027551578593
   PubMed Web of Science ®Google Scholar
• JohnsonRE.EissenbergT.StitzerML.et al.Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.Drug Alcohol Depend.19954027358746921
   PubMed Web of Science ®Google Scholar
• FiellinDA.KleberHD.Trumble-HejdukJG.et al.Consensus statement of office-based treatment of opioid dependence using buprenorphine.J Sub Abuse Treatment200427153159
   PubMed Web of Science ®Google Scholar
• TorringtonM.DomierCP.HillhouseM.et al.Buprenorphine 101: Treating Opioid dependence with buprenorphine in an office-based setting.J Addict Dis.200726939918018812
   PubMed Web of Science ®Google Scholar
• MeierBR.PatkarAA.Buprenorphine treatment: factors and first-hand experiences for providers to consider.J Addict Dis.20072631417439863
   PubMed Web of Science ®Google Scholar
• AuriacombeM.FranquesP.TignolJ.Deaths attributable to methadone vs buprenorphine in France.JAMA.20014511150107
   PubMed Web of Science ®Google Scholar
• MendelsonJ.UptonRA.EverhartET.et al.Bioavailability of sublingual buprenorphine.J Clin Pharmacol.19973731379048270
   PubMed Web of Science ®Google Scholar
• StrainEC.MoodyDE.StollerKB.et al.Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.Drug Alcohol Depend.200474374315072805
   PubMed Web of Science ®Google Scholar
• WalshSL.EissenbergT.The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic.Drug Alcohol Depend.200370(2Suppl)S132712738347
   PubMed Web of Science ®Google Scholar
• ComerSD.CollinsED.FischmanMW.Intravenous buprenorphine selfadministration by detoxified heroin abusers.J Pharmacol Exp Ther.200230126627611907183
   PubMed Web of Science ®Google Scholar
• ObadiaY.PerrinV.FeroniI.et al.Injecting misuse of buprenorphine among French drug users.Addiction.20019626727211182872
   PubMed Web of Science ®Google Scholar
• PartanenA.MakiJ.Buprenorphine more common as a problem drug in Finland, Nordic Studies on Alcohol and Drugs.Nordisk Alkohl - & Narkoikatidskrift (NAT), English Supplement.2004156161
   Google Scholar
• SakolMS.StarkC.SykesR.Buprenorphine and temazepam abuse by drug takers in Glasgow - an increase.Br J Addict.1989844394412566343
   PubMedGoogle Scholar
• JenkinsonRA.ClarkNC.FryCL.et al.Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?Addiction.200510019720515679749
   PubMed Web of Science ®Google Scholar
• AlhoH.SinclairD.VuoriE.et al.Abuse liability of buprenorphinenaloxone tablets in untreated IV drug users.Drug Alcohol Depend.200788757817055191
   PubMed Web of Science ®Google Scholar
• KobayashiK.YamamotoT.ChibaK.et al.Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.Drug Metab Dispos.1998268188219698298
   PubMed Web of Science ®Google Scholar
• CarrieriMP.VlahovD.DellamonicaP.et al.Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.Drug Alcohol Depend.200060515410821989
   PubMed Web of Science ®Google Scholar
• BruceRD.McCance-KatzE.KharaschED.et al.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Clin Infect Dis.200643(suppl4)S216S22317109308
   PubMed Web of Science ®Google Scholar
• BruceRD.AlticeFL.GourevitchMN.et al.Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.J Acquir Immune Defic Syndr.20064156357216652030
   PubMed Web of Science ®Google Scholar
• MelloNK.MendelsonJH.KuehnleJC.Buprenorphine effects on human heroin self-administration: an operant analysis.J Pharmacol Exp Ther.198222330397120124
   PubMed Web of Science ®Google Scholar
• ComerSD.CollinsED.FischmanMW.Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.Psychopharmacology (Berl).2001154283711292003
   PubMed Web of Science ®Google Scholar
• JohnsonRE.ChutuapeMA.StrainEC.et al.A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.N Engl J Med.20003431290129711058673
   PubMed Web of Science ®Google Scholar
• KreekMJ.LaForgeKS.ButelmanE.Pharmacotherapy of addictions.Nat Rev Drug Discov.2002171072612209151
   PubMed Web of Science ®Google Scholar
• MattickRP.KimberJ.BreenC.et al.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.Cochrane Database Syst Rev.2003CD00220712804429
   PubMedGoogle Scholar
• KakkoJ.GronbladhL.SvanborgKD.et al.A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.Am J Psychiatry.200716479780317475739
   PubMed Web of Science ®Google Scholar
• KintzP.Deaths involving buprenorphine: a compendium of French cases.Forensic Sci Int.2001121656911516889
   PubMed Web of Science ®Google Scholar
• MontoyaID.GorelickDA.PrestonKL.et al.Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.Clin Pharmacol Ther.200475344814749690
   PubMed Web of Science ®Google Scholar
• KostenTR.KleberHD.MorganC.Treatment of cocaine abuse with buprenorphine.Biol Psychiatry.1989266376392790101
   PubMed Web of Science ®Google Scholar
• StrainEC.StitzerML.LiebsonIA.et al.Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addict ion severity index.J Clin Psychopharmacol.19961658678834420
   PubMed Web of Science ®Google Scholar
• SchottenfeIdRS.PakesJR.OlivetoA.et al.Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.Arch Gen Psychiatry.1997547137209283506
   PubMed Web of Science ®Google Scholar
• BroonerRK.KidorfMS.KingVL.et al.Behavioral contingencies improve counseling attendance in an adaptive treatment model.J Subst Abuse Treat20042722323215501375
   PubMed Web of Science ®Google Scholar
• MaguraS.LeeSJ.SalsitzEA.et al.Outcomes of buprenorphine maintenance in office-based practice.J Addict Dis.200726132317594994
   PubMed Web of Science ®Google Scholar
• LofwallMR.StitzerML.et al.Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence.Addict Disorders Treat200544964
   Google Scholar
• WedamEF.Haigney.MCP.et al.EKG QT-proIongation effects of methadone, LAAM, and buprenorphine in a randomized trial, inCollege on Problems of Drug Dependence Annual Conference. San Juan, Puerto Rico,2004
   Google Scholar
• DyerKR.FosterDJ.WhiteJM.et al.Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.Clin Pharmacol Ther.19996568569410391674
   PubMed Web of Science ®Google Scholar
• DyerKR.WhiteJM.FosterDJ.et al.The relationship between mood state and plasma methadone concentration in maintenance patients.J Clin Psychopharmacol.200121788411199952
   PubMed Web of Science ®Google Scholar
• RobertsDM.Meyer-WittingM.High-dose buprenorphine: perioperative precautions and management strategies.Anaesth Intensive Care.200533172515957687
   PubMed Web of Science ®Google Scholar
• BeckerAB.StrainEC.BigelowGE.et al.Gradual dose taper following chronic buprenorphine.Am J Addict20011011112111444154
   PubMed Web of Science ®Google Scholar
• AmassL.BickelWK.HigginsST.et al.A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification.J Addict Dis.19941333457734458
   PubMed Web of Science ®Google Scholar
• KostenTR.KleberHD.Buprenorphine detoxification from opioid dependence: a pilot study.Life Sci.1988426356413276999
   PubMed Web of Science ®Google Scholar
• KostenTR.MorganC.KleberHD.Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.NIDA Res Monogr.19921211011191406906
   PubMedGoogle Scholar
• O'BrienCP.KampmanKM.Opioids: antagonists and partial agonists. In: Galanter M, Kleber HD.Textbook of Substance Abuse Treatment. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc;2004305319
   Google Scholar
• KleberHD.KostenTR.GaspariJ.et al.Nontolerance to the opioid antagonism of naltrexone.Biol Psychiatry.19852066722981129
   PubMed Web of Science ®Google Scholar
• GarbuttJC.KranzlerHR.O'MalleySS.et al.Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.JAMA.20052931617162515811981
   PubMed Web of Science ®Google Scholar
• ComerSD.SullivanMA.YuE.et al.Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebocontrolled trial.Arch Gen Psychiatry.20066321021816461865
   PubMed Web of Science ®Google Scholar
• WashtonAM.PottashAC.GoldMS.Naltrexone in addicted business executives and physicians.J Clin Psychiatry.19844539416088468
   PubMed Web of Science ®Google Scholar
• O'BrienC.CornishJW.Naltrexone for probationers and parolees.J Subst Abuse Treat20063110711116919734
   PubMed Web of Science ®Google Scholar
• CornishJW.HensonD.LevineS.Naltrexone maintenance: Effect on morphine sensitivity in normal volunteers.Am J Addict.199323438
   PubMedGoogle Scholar
• TennantFS.Jr.RawsonRA.CohenAJ.et al.Clinical experience with naltrexone in suburban opioid addicts.J Clin Psychiatry.19844542456469935
   PubMed Web of Science ®Google Scholar
• RothA.HoganI.FarrenC.Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals.J Subst Abuse Treat.19971419229218232
   PubMed Web of Science ®Google Scholar
• KrupitskyEM.ZvartauEE.MasalovDV.et al.Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.J Subst Abuse Treat20063131932817084785
   PubMed Web of Science ®Google Scholar
• FudaIaPJ.BerkowLC.FralichJL.et al.Use of naloxone in the assessment of opiate dependence.Life Sci.199149180918141943484
   PubMed Web of Science ®Google Scholar
• PeacheyJE.LeiH.Assessment of opioid dependence with naloxone.Br J Addict.1988831932013345396
   PubMedGoogle Scholar
• CarrollKM.BallSA.NichC.et al.Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.Arch Gen Psychiatry.20015875576111483141
   PubMed Web of Science ®Google Scholar
• Fals-StewartW.O'FarrellTJ.Behavioral family counseling and naltrexone for male opioid-dependent patients.J Consult Clin Psychol.20037143244212795568
   PubMed Web of Science ®Google Scholar
• RothenbergJL.SullivanMA.ChurchSH.et al.Behavioral naltrexone therapy: an integrated treatment for opiate dependence.J Subst Abuse Treat.20022335136012495797
   PubMed Web of Science ®Google Scholar
• NunesEV.RothenbergJL.SullivanMA.et al.Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?Am J Drug Alcohol Abuse.20063250351717127538
   PubMed Web of Science ®Google Scholar
• PrestonKL.SilvermanK.UmbrichtA.et al.Improvement in naltrexone treatment compliance with contingency management.Drug Alcohol Depend.1999541273510217552
   PubMed Web of Science ®Google Scholar
• CarrollKM.Recent advances in the psychotherapy of addictive disorders.Curr Psychiatry Rep.2005732933616216150
   PubMedGoogle Scholar
• MarrazziMA.WroblewskiJM.KinzieJ.et al.High-dose naltrexone and liver function safety.Am J Addict1997621299097868
   PubMed Web of Science ®Google Scholar
• ArndtID.CacciolaJS.McLellanAT.A re-evaluation of naltrexone toxicity in recovering opiate addicts. In: Harris LS, ed. Problems of Drug Dependence. Rockville, Md: National Institute on Drug Abuse.NIDA Res Monogr.198667S25
   Google Scholar
• PfohlDN.AllenJI.AtkinsonRL.et al.Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.NIDA Res Monogr.19866766723092099
   PubMedGoogle Scholar
• VerebeyK.VolavkaJ.MuleSJ.et al.Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.Clin Pharmacol Ther.197620315328954353
   PubMed Web of Science ®Google Scholar
• VolavkaJ.ChoD.MallyaA.et al.Naloxone increases ACTH and Cortisol levels in man.N Engl J Med.197930010561057219337
   PubMed Web of Science ®Google Scholar
• MendelsonJH.EllingboeJ.KuehnleJ.et al.Heroin and naltrexone effects on pituitary-gonadal hormones in man: tolerance and supersensitivity.NIDA Res Monogr.197927302308121347
   PubMedGoogle Scholar
• MendelsonJH.EllingboeJ.KeuhnleJC.et al.Effects of naltrexone on mood and neuroendocrine function in normal adult males.Psychoneuroendocrinology.19783231236219434
   PubMed Web of Science ®Google Scholar
• KirchmayerU.DavoliM.VersterA.Naltrexone maintenance treatment for opioid dependence.Cochrane Database Syst Rev.2003CD00133312804405
   PubMedGoogle Scholar
• BartuA.FreemanNC.GawthorneGS.et al.Characteristics, retention and réadmissions of opioid-dependent clients treated with oral naltrexone.Drug Alcohol Rev.20022133534012537702
   PubMed Web of Science ®Google Scholar